UK Markets close in 5 hrs 29 mins

BRIEF-Preliminary 19.2 vs 14.4 months OS benefit in Roche lung cancer trial

Dec 7 (Reuters) - Principal investigator on Roche Impower 150 clinical trial tells press conference in Geneva:

* IMPOWER 150 LUNG CANCER STUDY SHOWS PRELIMINARY OVERALL SURVIVAL BENEFIT OF 19.2 MONTHS VERSUS 14.4 MONTHS, HAZARD RATIO 0.775; DATA NOT YET MATURE Further company coverage: (Reporting by UK bureau)

See Also: